Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.24
DEPO's Cash to Debt is ranked lower than
84% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. DEPO: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 11.79 Max: No Debt
Current: 0.24
Equity to Asset 0.22
DEPO's Equity to Asset is ranked lower than
92% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DEPO: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s Equity to Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.36 Max: 0.97
Current: 0.22
-2.63
0.97
F-Score: 2
Z-Score: 0.81
M-Score: 0.25
WACC vs ROIC
11.56%
-3.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.80
DEPO's Operating margin (%) is ranked lower than
80% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. DEPO: -10.80 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s Operating margin (%) Range Over the Past 10 Years
Min: -435.63  Med: -5.11 Max: 72.49
Current: -10.8
-435.63
72.49
Net-margin (%) -20.47
DEPO's Net-margin (%) is ranked lower than
83% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. DEPO: -20.47 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s Net-margin (%) Range Over the Past 10 Years
Min: -415.23  Med: -8.64 Max: 75.05
Current: -20.47
-415.23
75.05
ROE (%) -25.57
DEPO's ROE (%) is ranked lower than
82% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. DEPO: -25.57 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s ROE (%) Range Over the Past 10 Years
Min: -90.05  Med: 20.07 Max: 532.43
Current: -25.57
-90.05
532.43
ROA (%) -6.98
DEPO's ROA (%) is ranked lower than
77% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. DEPO: -6.98 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s ROA (%) Range Over the Past 10 Years
Min: -66.64  Med: -1.47 Max: 73.87
Current: -6.98
-66.64
73.87
ROC (Joel Greenblatt) (%) -39.52
DEPO's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. DEPO: -39.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2282.52  Med: -160.86 Max: 8060.52
Current: -39.52
-2282.52
8060.52
Revenue Growth (3Y)(%) 51.90
DEPO's Revenue Growth (3Y)(%) is ranked higher than
95% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DEPO: 51.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.4  Med: 35.40 Max: 517.8
Current: 51.9
-74.4
517.8
EPS Growth (3Y)(%) 33.20
DEPO's EPS Growth (3Y)(%) is ranked higher than
82% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. DEPO: 33.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.8  Med: -5.10 Max: 180.8
Current: 33.2
-58.8
180.8
» DEPO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

DEPO Guru Trades in Q2 2015

Paul Tudor Jones 26,100 sh (-38.46%)
Joel Greenblatt 842,188 sh (-40.46%)
» More
Q3 2015

DEPO Guru Trades in Q3 2015

Jim Simons 104,146 sh (New)
Paul Tudor Jones 40,800 sh (+56.32%)
Joel Greenblatt 264,236 sh (-68.63%)
» More
Q4 2015

DEPO Guru Trades in Q4 2015

John Hussman 200,000 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones 30,900 sh (-24.26%)
» More
Q1 2016

DEPO Guru Trades in Q1 2016

Steven Cohen 1,866,629 sh (New)
John Hussman 200,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:LCI, OTCPK:GNMLF, NAS:SUPN, NAS:CPXX, NAS:PCRX, NAS:MNTA, NAS:AMPH, NAS:ACET, NAS:SGYP, NAS:EGRX, NAS:SGNT, OTCPK:KHTRF, NAS:HRTX, OTCPK:EVTCY, NAS:INNL, NAS:SCMP, NAS:SCLN, NAS:LBIO, NAS:RDUS, NAS:FLXN » details
Traded in other countries:DPO.Germany,
DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.

Ratios

vs
industry
vs
history
Forward P/E 15.97
DEPO's Forward P/E is ranked higher than
53% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. DEPO: 15.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 15.40
DEPO's Price/Owner Earnings (ttm) is ranked higher than
82% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. DEPO: 15.40 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DEPO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.68  Med: 7.47 Max: 212
Current: 15.4
2.68
212
P/B 3.86
DEPO's P/B is ranked lower than
63% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. DEPO: 3.86 )
Ranked among companies with meaningful P/B only.
DEPO' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.17 Max: 22.64
Current: 3.86
2
22.64
P/S 2.78
DEPO's P/S is ranked higher than
50% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. DEPO: 2.78 )
Ranked among companies with meaningful P/S only.
DEPO' s P/S Range Over the Past 10 Years
Min: 1.38  Med: 3.47 Max: 210.94
Current: 2.78
1.38
210.94
PFCF 8.93
DEPO's PFCF is ranked higher than
86% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. DEPO: 8.93 )
Ranked among companies with meaningful PFCF only.
DEPO' s PFCF Range Over the Past 10 Years
Min: 2.31  Med: 9.11 Max: 265.87
Current: 8.93
2.31
265.87
POCF 8.80
DEPO's POCF is ranked higher than
82% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. DEPO: 8.80 )
Ranked among companies with meaningful POCF only.
DEPO' s POCF Range Over the Past 10 Years
Min: 2.28  Med: 8.95 Max: 251.36
Current: 8.8
2.28
251.36
EV-to-EBITDA 26.77
DEPO's EV-to-EBITDA is ranked lower than
70% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. DEPO: 26.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: -0.50 Max: 124.5
Current: 26.77
-582.9
124.5
Shiller P/E 155.74
DEPO's Shiller P/E is ranked lower than
90% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. DEPO: 155.74 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s Shiller P/E Range Over the Past 10 Years
Min: 84.17  Med: 134.00 Max: 387.25
Current: 155.74
84.17
387.25
Current Ratio 0.95
DEPO's Current Ratio is ranked lower than
89% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. DEPO: 0.95 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3.00 Max: 56
Current: 0.95
0.57
56
Quick Ratio 0.91
DEPO's Quick Ratio is ranked lower than
79% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. DEPO: 0.91 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3.00 Max: 56
Current: 0.91
0.57
56
Days Inventory 40.93
DEPO's Days Inventory is ranked higher than
87% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. DEPO: 40.93 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 50.93  Med: 226.72 Max: 613.73
Current: 40.93
50.93
613.73
Days Sales Outstanding 61.43
DEPO's Days Sales Outstanding is ranked higher than
60% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. DEPO: 61.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 347.08
Current: 61.43
12.13
347.08
Days Payable 30.46
DEPO's Days Payable is ranked lower than
86% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. DEPO: 30.46 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 128.77 Max: 1113.92
Current: 30.46
30.8
1113.92

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.30
DEPO's Price/Projected FCF is ranked higher than
53% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. DEPO: 2.30 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.18  Med: 2.94 Max: 335
Current: 2.3
1.18
335
Price/Median PS Value 0.78
DEPO's Price/Median PS Value is ranked higher than
79% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. DEPO: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 3.57 Max: 394
Current: 0.78
0.43
394
Earnings Yield (Greenblatt) (%) -2.50
DEPO's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DEPO: -2.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.53  Med: 17.25 Max: 266.4
Current: -2.5
-2.53
266.4

More Statistics

Revenue (TTM) (Mil) $415.3
EPS (TTM) $ -1.41
Beta1.50
Short Percentage of Float24.52%
52-Week Range $12.25 - 33.17
Shares Outstanding (Mil)61.10

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 487 597 689
EPS ($) 1.19 1.69 2.18
EPS w/o NRI ($) 1.19 1.69 2.18
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 Jul 27 2016
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 Jul 27 2016
DepoMed downgraded by Piper Jaffray Jul 27 2016
9:14 am DepoMed: Starboard delivers letter to shareholders, says moving forward with consent... Jul 26 2016
Starboard Delivers Letter To Depomed Shareholders Jul 26 2016
Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent Jul 18 2016
Coverage Initiated on Select Drug Manufacturer Stocks Jul 15 2016
Depomed Releases Lazanda® 300 mcg Dose for Treatment of Breakthrough Cancer Pain Jul 08 2016
Depomed Downgraded On Weakness In Base Business, Stock Run-Up Jul 07 2016
Depomed to Present at the Cantor Fitzgerald Healthcare Conference Jul 06 2016
Depomed to Present at the Cantor Fitzgerald Healthcare Conference Jul 06 2016
Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : June 28, 2016 Jun 28 2016
Depomed to call special meeting of shareholders on Oct 28 Jun 24 2016
DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2016
Depomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of... Jun 23 2016
Depomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of... Jun 23 2016
Depomed to Present at the JMP Securities Life Sciences Conference Jun 14 2016
Depomed to Present at the JMP Securities Life Sciences Conference Jun 14 2016
Featured Research Report on Drug Manufacturers Stocks Jun 14 2016
RIMA Senvest Grows Even More Bullish On Top Holdings Jun 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)